????英國藥業巨頭葛蘭素史克（GlaxoSmithKline）正在接受英國反嚴重欺詐辦公室（Serious Fraud Office，SFO）對其商業行為的調查。

????這家公司自稱堅持“最高的道德標準”，并將“全力配合”政府調查。反嚴重欺詐辦公室在一份聲明中寫道：“反嚴重欺詐辦公室主任已經開始對葛蘭素史克及其子公司的商業行為展開刑事調查。”但這份聲明沒有詳細說明這家公司非法活動的性質。

????本月早些時候，中國執法部門指控葛蘭素史克賄賂醫院和政府官員。當時，中國官方指控葛蘭素史克前中國區負責人馬克銳在中國建立了“龐大的賄賂網絡”。

????針對上述指控，葛蘭素史克在聲明中回應稱：“我們非常認真地對待中方提出的指控。我們對這些指控深表關切，這種行為違反了葛蘭素史克的價值。我們將繼續全力配合相關部門對該事件進行調查。”

????BBC4月份報道稱，在波蘭，11名醫生和這家制藥公司的一名區域經理因為2010年至2012年期間的腐敗行為而遭到了指控。

????據BBC報道，如果最近的指控屬實，那么，這家公司可能已經違反了英國《反賄賂法》（UK Bribery Act）和美國《反海外腐敗法》（US Foreign Corrupt Practices Act）。

????目前尚無其他詳細信息。葛蘭素史克發言人也拒絕就此發表評論。（財富中文網）

????譯者：劉進龍/汪皓

????GlaxoSmithKline (GSK), the British pharmaceutical giant, is under investigation by the UK's Serious Fraud Office (SFO) over its commercial practices.

????According to the company, it intends to uphold the "highest ethical standards" and will "cooperate fully" with the government inquiry. In a statement, the SFO wrote, "The Director of the SFO has opened a criminal investigation into the commercial practices of GlaxoSmithKline plc and its subsidiaries." It did not elaborate any further about the nature of any illegal activity by the company.

????Earlier this month, Chinese law enforcement accused GlaxoSmithKline of bribing hospital and government officials. At that time, Chinese authorities said GlaxoSmithKline's former China chief Mark Reilly was responsible for starting a "massive bribery network" in the country.

????In response to those accusations, GlaxoSmithKline said in a statement: "We take the allegations that have been raised very seriously. They are deeply concerning to us and contrary to the values of GlaxoSmithKline. We will continue to fully co-operate with the authorities in this matter."

????In Poland, meanwhile, 11 doctors and a regional manager for the pharmaceutical company were charged with corruption from 2010 to 2012, according to the BBC in April.

????If the latest allegations prove true, the company may have violated the UK Bribery Act and the US Foreign Corrupt Practices Act, according to the BBC.

????No other details were immediately available. A spokeswoman for GlaxoSmithKline declined to comment.